Qualcomm collaborates with PAREXEL International to power connected clinical trials

JUN 19, 2017 | San Diego

Qualcomm Incorporated (NASDAQ: QCOM), through its subsidiary Qualcomm Life, Inc ., today announced its collaboration with PAREXEL International Corporation (NASDAQ: PRXL) to expand PAREXEL’s clinical technology service offerings to include a connected sensor platform to digitize clinical trials. PAREXEL, a leading biopharmaceutical services company, is leveraging Qualcomm Life'€™s 2net™ medical-grade solution and ecosystem of integrated medical devices in its recently launched Patient Sensor Solution , an end-to-end services and technology solution that facilitates the remote collection of study subject data via medical devices.

“Companies across the life science industry are increasingly looking for ways to conduct clinical trials more effectively and efficiently by incorporating alternative data solutions to better meet today’s evolving regulatory and payer standards,” said Xavier Flinois, President, PAREXEL Informatics. “Qualcomm Life’s 2net connectivity solution and ecosystem of integrated medical devices provides our Patient Sensor Solution with the secure infrastructure needed to deliver greater efficiencies for sponsors, allowing them to generate clinical and quality-of-life endpoints via medical devices and distinguish treatments from competition through remote monitoring.”

PAREXEL is leveraging Qualcomm Life’s platform to securely capture, transmit, store, and visualize patient data during clinical trials. With this platform, PAREXEL aims to improve the accuracy and timeliness of data collection to maximize efficiencies, reduce costs, and gain a more holistic view of trial participants’ health. Qualcomm Life’s 2net Quality Management System is based on FDA and EU-MDD regulations, and is ISO 13485:2003 certified and designed to HIPAA privacy and security standards.

“We are honored to be working with PAREXEL, a global leader in clinical development solutions, to provide connectivity capabilities to its clinical trial platform,” said Rick Valencia, president, Qualcomm Life. “Through this collaboration, we aim to help PAREXEL in streamlining clinical trials to improve accuracies, create efficiencies for clinicians and trial participants, enabling more timely, informed care.”